Atlas Trials

CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma

Clinical trial NCT04578600 · COMPLETED

Trial details

NCT number
NCT04578600
Sponsor
Joseph Tuscano
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Indolent B-Cell Non-Hodgkin LymphomaRecurrent B-Cell Non-Hodgkin LymphomaRecurrent Chronic Lymphocytic LeukemiaRecurrent Mucosa-Associated Lymphoid Tissue LymphomaRecurrent Follicular LymphomaRecurrent Hairy Cell LeukemiaRecurrent Lymphoplasmacytic LymphomaRecurrent Mantle Cell LymphomaRecurrent Marginal Zone LymphomaRefractory B-Cell Non-Hodgkin LymphomaRefractory Chronic Lymphocytic LeukemiaRefractory Mucosa-Associated Lymphoid Tissue Lymphoma
Start date
2020-10-23
Primary completion
2023-12-12
Enrollment
8

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.